| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 180 | 2026 | 2332 | 22.710 |
Why?
|
| Cardiology | 55 | 2026 | 514 | 7.890 |
Why?
|
| Stroke Volume | 46 | 2026 | 541 | 5.340 |
Why?
|
| American Heart Association | 54 | 2026 | 343 | 5.190 |
Why?
|
| Cardiovascular Diseases | 32 | 2026 | 2121 | 2.580 |
Why?
|
| Consensus | 20 | 2025 | 512 | 2.540 |
Why?
|
| Women's Health | 5 | 2021 | 134 | 2.490 |
Why?
|
| Advisory Committees | 20 | 2022 | 150 | 2.190 |
Why?
|
| Humans | 294 | 2026 | 131163 | 2.150 |
Why?
|
| Angiotensin Receptor Antagonists | 11 | 2026 | 133 | 1.980 |
Why?
|
| Myocarditis | 6 | 2024 | 122 | 1.860 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2023 | 362 | 1.770 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2026 | 853 | 1.750 |
Why?
|
| Cardiomyopathies | 13 | 2023 | 514 | 1.730 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2025 | 214 | 1.650 |
Why?
|
| Hospitalization | 22 | 2026 | 1950 | 1.600 |
Why?
|
| Biomarkers | 32 | 2026 | 3385 | 1.570 |
Why?
|
| Myocardial Infarction | 12 | 2025 | 999 | 1.510 |
Why?
|
| Obesity | 15 | 2026 | 2426 | 1.480 |
Why?
|
| Aminobutyrates | 6 | 2026 | 10 | 1.450 |
Why?
|
| United States | 86 | 2026 | 12072 | 1.450 |
Why?
|
| Cardiac Resynchronization Therapy | 4 | 2025 | 49 | 1.450 |
Why?
|
| Disease Management | 20 | 2026 | 558 | 1.420 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2018 | 110 | 1.340 |
Why?
|
| Clinical Trials as Topic | 18 | 2026 | 1129 | 1.330 |
Why?
|
| Prognosis | 34 | 2026 | 4886 | 1.300 |
Why?
|
| Ventricular Function, Left | 18 | 2026 | 549 | 1.220 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 8 | 2026 | 45 | 1.180 |
Why?
|
| Practice Guidelines as Topic | 23 | 2026 | 1295 | 1.160 |
Why?
|
| Natriuretic Peptide, Brain | 11 | 2026 | 325 | 1.160 |
Why?
|
| Societies, Medical | 14 | 2026 | 798 | 1.080 |
Why?
|
| Ventricular Remodeling | 9 | 2020 | 155 | 1.080 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 339 | 1.040 |
Why?
|
| Metabolic Syndrome | 6 | 2026 | 369 | 1.030 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 351 | 1.000 |
Why?
|
| Heart Diseases | 7 | 2023 | 499 | 0.990 |
Why?
|
| Research Report | 9 | 2022 | 73 | 0.990 |
Why?
|
| Stroke | 3 | 2023 | 1061 | 0.970 |
Why?
|
| Defibrillators, Implantable | 3 | 2025 | 215 | 0.960 |
Why?
|
| Biphenyl Compounds | 6 | 2026 | 75 | 0.950 |
Why?
|
| Valsartan | 5 | 2026 | 24 | 0.940 |
Why?
|
| Treatment Outcome | 45 | 2026 | 12936 | 0.920 |
Why?
|
| Anti-Obesity Agents | 4 | 2026 | 47 | 0.920 |
Why?
|
| Albuminuria | 1 | 2025 | 107 | 0.860 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2020 | 187 | 0.860 |
Why?
|
| Databases, Factual | 6 | 2020 | 1240 | 0.850 |
Why?
|
| Troponin I | 2 | 2018 | 122 | 0.850 |
Why?
|
| Risk Assessment | 20 | 2025 | 3711 | 0.820 |
Why?
|
| Cardiac Rehabilitation | 2 | 2021 | 29 | 0.820 |
Why?
|
| Risk Factors | 40 | 2026 | 11074 | 0.810 |
Why?
|
| Evidence-Based Medicine | 12 | 2026 | 645 | 0.790 |
Why?
|
| Betacoronavirus | 4 | 2020 | 275 | 0.780 |
Why?
|
| Blood Pressure | 9 | 2025 | 1345 | 0.780 |
Why?
|
| Female | 89 | 2026 | 70963 | 0.780 |
Why?
|
| Concept Formation | 1 | 2023 | 27 | 0.760 |
Why?
|
| Tetrazoles | 5 | 2026 | 70 | 0.750 |
Why?
|
| Cardiovascular System | 5 | 2022 | 97 | 0.750 |
Why?
|
| Peripheral Arterial Disease | 3 | 2023 | 326 | 0.740 |
Why?
|
| Periodicals as Topic | 5 | 2023 | 182 | 0.740 |
Why?
|
| Cardio-Renal Syndrome | 3 | 2026 | 24 | 0.710 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2025 | 216 | 0.700 |
Why?
|
| Aged | 53 | 2026 | 21025 | 0.690 |
Why?
|
| Middle Aged | 60 | 2026 | 28601 | 0.670 |
Why?
|
| Male | 82 | 2026 | 64957 | 0.660 |
Why?
|
| Autoantigens | 1 | 2021 | 97 | 0.660 |
Why?
|
| Registries | 9 | 2026 | 1634 | 0.650 |
Why?
|
| Comorbidity | 13 | 2022 | 1595 | 0.640 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 215 | 0.630 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 523 | 0.610 |
Why?
|
| Cardiovascular Agents | 5 | 2024 | 88 | 0.600 |
Why?
|
| Pandemics | 7 | 2022 | 1118 | 0.590 |
Why?
|
| Acute Disease | 10 | 2026 | 1153 | 0.590 |
Why?
|
| Digoxin | 2 | 2010 | 37 | 0.590 |
Why?
|
| Health Status Disparities | 3 | 2019 | 282 | 0.590 |
Why?
|
| Sex Factors | 11 | 2021 | 1356 | 0.590 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2016 | 45 | 0.580 |
Why?
|
| Electrocardiography | 5 | 2024 | 970 | 0.580 |
Why?
|
| Dyspnea | 2 | 2014 | 159 | 0.560 |
Why?
|
| Hypotension | 3 | 2025 | 187 | 0.560 |
Why?
|
| Heart Transplantation | 9 | 2026 | 800 | 0.550 |
Why?
|
| Peripartum Period | 5 | 2021 | 29 | 0.540 |
Why?
|
| Atherosclerosis | 7 | 2023 | 948 | 0.530 |
Why?
|
| Quality of Life | 8 | 2026 | 2082 | 0.530 |
Why?
|
| Telemedicine | 3 | 2026 | 526 | 0.520 |
Why?
|
| Primary Prevention | 5 | 2024 | 183 | 0.520 |
Why?
|
| Drug Combinations | 4 | 2026 | 270 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2010 | 639 | 0.520 |
Why?
|
| Heart-Assist Devices | 3 | 2023 | 1020 | 0.510 |
Why?
|
| Hyperkalemia | 4 | 2026 | 68 | 0.500 |
Why?
|
| Incidence | 11 | 2023 | 3360 | 0.500 |
Why?
|
| Puerperal Disorders | 4 | 2017 | 47 | 0.500 |
Why?
|
| Atrial Pressure | 1 | 2016 | 6 | 0.480 |
Why?
|
| Hyperlipidemias | 2 | 2016 | 185 | 0.480 |
Why?
|
| Hospital Mortality | 9 | 2023 | 1064 | 0.480 |
Why?
|
| Disease Progression | 12 | 2026 | 2200 | 0.470 |
Why?
|
| Inpatients | 1 | 2020 | 562 | 0.470 |
Why?
|
| Goals | 4 | 2026 | 126 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2025 | 1459 | 0.460 |
Why?
|
| Lung Diseases | 2 | 2014 | 398 | 0.460 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 705 | 0.460 |
Why?
|
| Biomedical Technology | 2 | 2026 | 38 | 0.460 |
Why?
|
| Losartan | 2 | 2026 | 36 | 0.460 |
Why?
|
| Prednisolone | 2 | 2026 | 74 | 0.450 |
Why?
|
| Cocaine | 1 | 2017 | 211 | 0.450 |
Why?
|
| Global Health | 2 | 2026 | 626 | 0.450 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 889 | 0.450 |
Why?
|
| Health Promotion | 1 | 2019 | 422 | 0.440 |
Why?
|
| Severity of Illness Index | 13 | 2026 | 3061 | 0.440 |
Why?
|
| Cocaine-Related Disorders | 1 | 2017 | 205 | 0.440 |
Why?
|
| Cytokines | 11 | 2021 | 1339 | 0.430 |
Why?
|
| Cardiotonic Agents | 2 | 2023 | 138 | 0.430 |
Why?
|
| Mortality | 4 | 2024 | 264 | 0.430 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2024 | 14 | 0.430 |
Why?
|
| Coronary Artery Bypass | 5 | 2021 | 515 | 0.430 |
Why?
|
| Inflammation | 3 | 2026 | 1489 | 0.420 |
Why?
|
| Hypertension | 4 | 2021 | 1356 | 0.420 |
Why?
|
| Exercise Test | 4 | 2024 | 239 | 0.420 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2014 | 46 | 0.420 |
Why?
|
| Europe | 5 | 2026 | 365 | 0.400 |
Why?
|
| Time Factors | 16 | 2025 | 6196 | 0.380 |
Why?
|
| Diuretics | 4 | 2023 | 159 | 0.380 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 395 | 0.380 |
Why?
|
| Neurotransmitter Agents | 3 | 2012 | 134 | 0.380 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2020 | 299 | 0.370 |
Why?
|
| Peptide Fragments | 6 | 2026 | 687 | 0.370 |
Why?
|
| Ventricular Pressure | 2 | 2011 | 34 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 425 | 0.370 |
Why?
|
| Patient Readmission | 5 | 2026 | 442 | 0.360 |
Why?
|
| Perioperative Care | 4 | 2015 | 217 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1267 | 0.360 |
Why?
|
| Myocardial Contraction | 2 | 2011 | 241 | 0.360 |
Why?
|
| Propanolamines | 1 | 2011 | 18 | 0.360 |
Why?
|
| Follow-Up Studies | 15 | 2026 | 5196 | 0.350 |
Why?
|
| Carbazoles | 1 | 2011 | 30 | 0.350 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 197 | 0.350 |
Why?
|
| Chronic Disease | 7 | 2022 | 1246 | 0.350 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 73 | 0.350 |
Why?
|
| Hypoglycemic Agents | 5 | 2025 | 480 | 0.350 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2020 | 117 | 0.340 |
Why?
|
| Chest Pain | 1 | 2012 | 133 | 0.340 |
Why?
|
| Adult | 30 | 2026 | 31282 | 0.340 |
Why?
|
| Spironolactone | 3 | 2026 | 20 | 0.340 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 104 | 0.330 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 240 | 0.330 |
Why?
|
| Troponin T | 4 | 2016 | 259 | 0.330 |
Why?
|
| Endpoint Determination | 3 | 2015 | 58 | 0.330 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 50 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 4 | 2018 | 235 | 0.320 |
Why?
|
| Writing | 2 | 2021 | 59 | 0.320 |
Why?
|
| Sodium | 3 | 2023 | 280 | 0.310 |
Why?
|
| Body Mass Index | 8 | 2026 | 1717 | 0.310 |
Why?
|
| Cardiac Catheterization | 4 | 2016 | 630 | 0.310 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 152 | 0.310 |
Why?
|
| Time-to-Treatment | 2 | 2025 | 209 | 0.300 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 17 | 0.300 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 37 | 0.300 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 663 | 0.300 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 143 | 0.290 |
Why?
|
| Shock, Cardiogenic | 3 | 2023 | 176 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2013 | 388 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2026 | 1626 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 4 | 2025 | 566 | 0.280 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 110 | 0.280 |
Why?
|
| Machine Learning | 2 | 2024 | 387 | 0.280 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 887 | 0.280 |
Why?
|
| Diabetes Complications | 1 | 2009 | 197 | 0.270 |
Why?
|
| Heart Defects, Congenital | 6 | 2019 | 1889 | 0.270 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 35 | 0.270 |
Why?
|
| Survival Analysis | 7 | 2014 | 1483 | 0.270 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2021 | 245 | 0.270 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 179 | 0.260 |
Why?
|
| Hemodynamics | 8 | 2023 | 810 | 0.250 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 191 | 0.250 |
Why?
|
| Prospective Studies | 13 | 2025 | 6459 | 0.250 |
Why?
|
| Retrospective Studies | 20 | 2024 | 17753 | 0.250 |
Why?
|
| Kidney | 2 | 2018 | 1282 | 0.250 |
Why?
|
| Anemia | 3 | 2026 | 354 | 0.240 |
Why?
|
| Japan | 3 | 2021 | 161 | 0.240 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 369 | 0.240 |
Why?
|
| Research Design | 5 | 2020 | 716 | 0.240 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 39 | 0.240 |
Why?
|
| Glucagon-Like Peptides | 1 | 2026 | 40 | 0.240 |
Why?
|
| Prevalence | 8 | 2023 | 2701 | 0.230 |
Why?
|
| Delphi Technique | 2 | 2025 | 283 | 0.230 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2008 | 73 | 0.230 |
Why?
|
| Ultrasonography | 3 | 2012 | 943 | 0.230 |
Why?
|
| Terminology as Topic | 5 | 2026 | 226 | 0.230 |
Why?
|
| Cause of Death | 3 | 2017 | 506 | 0.230 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 143 | 0.230 |
Why?
|
| Hematinics | 1 | 2026 | 60 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 267 | 0.220 |
Why?
|
| Patient Selection | 5 | 2020 | 729 | 0.220 |
Why?
|
| Patient Care Planning | 1 | 2026 | 124 | 0.220 |
Why?
|
| Immunoglobulin G | 3 | 2008 | 786 | 0.220 |
Why?
|
| Aged, 80 and over | 12 | 2026 | 6797 | 0.220 |
Why?
|
| Critical Care | 2 | 2021 | 686 | 0.220 |
Why?
|
| Health Personnel | 2 | 2020 | 541 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2020 | 148 | 0.210 |
Why?
|
| Proportional Hazards Models | 6 | 2014 | 1410 | 0.210 |
Why?
|
| Echocardiography | 4 | 2023 | 1125 | 0.210 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 77 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2026 | 224 | 0.200 |
Why?
|
| Pain Management | 3 | 2015 | 205 | 0.200 |
Why?
|
| Heart Valve Prosthesis | 4 | 2013 | 303 | 0.200 |
Why?
|
| Nephrology | 1 | 2026 | 162 | 0.200 |
Why?
|
| Geriatric Assessment | 1 | 2025 | 184 | 0.200 |
Why?
|
| Confidence Intervals | 5 | 2010 | 272 | 0.200 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 57 | 0.200 |
Why?
|
| Transitional Care | 1 | 2023 | 16 | 0.200 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 162 | 0.200 |
Why?
|
| China | 2 | 2021 | 278 | 0.200 |
Why?
|
| Creatinine | 1 | 2025 | 398 | 0.200 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 36 | 0.200 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2024 | 176 | 0.190 |
Why?
|
| Aortic Valve | 4 | 2015 | 455 | 0.190 |
Why?
|
| Technology | 1 | 2023 | 68 | 0.190 |
Why?
|
| Sleep Apnea, Central | 1 | 2022 | 10 | 0.190 |
Why?
|
| Thalidomide | 1 | 2002 | 36 | 0.180 |
Why?
|
| Complementary Therapies | 1 | 2022 | 45 | 0.180 |
Why?
|
| Frailty | 1 | 2025 | 140 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 256 | 0.180 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 11 | 0.180 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2022 | 32 | 0.180 |
Why?
|
| Patient Care Team | 4 | 2015 | 562 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 4 | 2014 | 350 | 0.180 |
Why?
|
| Myocardium | 6 | 2021 | 852 | 0.180 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 376 | 0.180 |
Why?
|
| Glucosides | 1 | 2022 | 55 | 0.180 |
Why?
|
| Cohort Studies | 10 | 2016 | 5063 | 0.180 |
Why?
|
| Protein Precursors | 2 | 2021 | 140 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 414 | 0.180 |
Why?
|
| Heart Function Tests | 3 | 2014 | 51 | 0.180 |
Why?
|
| Survival Rate | 6 | 2017 | 2114 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 79 | 0.170 |
Why?
|
| Texas | 8 | 2017 | 3686 | 0.170 |
Why?
|
| Molecular Mimicry | 1 | 2021 | 17 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 227 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 33 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 1 | 2022 | 91 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2024 | 236 | 0.170 |
Why?
|
| New Zealand | 1 | 2021 | 63 | 0.170 |
Why?
|
| Specialization | 1 | 2021 | 75 | 0.170 |
Why?
|
| Educational Status | 1 | 2022 | 279 | 0.170 |
Why?
|
| Sexism | 1 | 2021 | 44 | 0.160 |
Why?
|
| Public Opinion | 1 | 2021 | 64 | 0.160 |
Why?
|
| Weight Loss | 4 | 2026 | 538 | 0.160 |
Why?
|
| Heart | 3 | 2022 | 650 | 0.160 |
Why?
|
| Shock, Septic | 1 | 2022 | 150 | 0.160 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 738 | 0.160 |
Why?
|
| Australia | 1 | 2021 | 173 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2021 | 54 | 0.160 |
Why?
|
| Health Status | 2 | 2020 | 378 | 0.160 |
Why?
|
| India | 1 | 2021 | 234 | 0.160 |
Why?
|
| Pregnancy | 6 | 2018 | 7512 | 0.160 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2022 | 170 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 573 | 0.160 |
Why?
|
| Length of Stay | 4 | 2021 | 1421 | 0.160 |
Why?
|
| Telemetry | 1 | 2020 | 23 | 0.160 |
Why?
|
| Occupational Health | 1 | 2020 | 43 | 0.160 |
Why?
|
| Canada | 1 | 2021 | 327 | 0.160 |
Why?
|
| Quality Improvement | 3 | 2024 | 722 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 71 | 0.150 |
Why?
|
| Neprilysin | 1 | 2019 | 16 | 0.150 |
Why?
|
| Enkephalins | 1 | 2019 | 19 | 0.150 |
Why?
|
| Social Media | 1 | 2021 | 120 | 0.150 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 88 | 0.150 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 30 | 0.150 |
Why?
|
| Standard of Care | 1 | 2020 | 133 | 0.150 |
Why?
|
| Ventricular Function, Right | 2 | 2018 | 126 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 144 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1490 | 0.140 |
Why?
|
| Quality of Health Care | 4 | 2015 | 413 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2019 | 61 | 0.140 |
Why?
|
| Nurse Practitioners | 2 | 2019 | 50 | 0.140 |
Why?
|
| Glucose | 1 | 2023 | 853 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 179 | 0.140 |
Why?
|
| Predictive Value of Tests | 6 | 2026 | 2304 | 0.140 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 232 | 0.140 |
Why?
|
| Leadership | 1 | 2021 | 255 | 0.140 |
Why?
|
| Hyponatremia | 2 | 2014 | 73 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 450 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2021 | 396 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 43 | 0.140 |
Why?
|
| Myocardial Ischemia | 2 | 2014 | 307 | 0.140 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 128 | 0.140 |
Why?
|
| Cardiac Output, Low | 1 | 1998 | 58 | 0.130 |
Why?
|
| Young Adult | 8 | 2026 | 10103 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2020 | 285 | 0.130 |
Why?
|
| Patient Discharge | 5 | 2022 | 514 | 0.130 |
Why?
|
| Research Personnel | 1 | 2019 | 139 | 0.130 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2024 | 268 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 314 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 402 | 0.130 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 63 | 0.120 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 226 | 0.120 |
Why?
|
| History, 21st Century | 2 | 2020 | 263 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 919 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3359 | 0.120 |
Why?
|
| Hepatomegaly | 1 | 2016 | 22 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 1168 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 193 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 3763 | 0.120 |
Why?
|
| Relaxin | 1 | 2016 | 16 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 1378 | 0.120 |
Why?
|
| Exercise | 2 | 2021 | 892 | 0.120 |
Why?
|
| Receptors, Glucagon | 2 | 2026 | 33 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2018 | 273 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 44 | 0.120 |
Why?
|
| Sweden | 2 | 2026 | 39 | 0.120 |
Why?
|
| Injections, Subcutaneous | 2 | 2026 | 136 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 99 | 0.120 |
Why?
|
| Prolactin | 1 | 2016 | 142 | 0.110 |
Why?
|
| Monocytes | 1 | 2017 | 335 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3829 | 0.110 |
Why?
|
| Edema | 1 | 2016 | 130 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2017 | 185 | 0.110 |
Why?
|
| Interleukin-6 | 3 | 2020 | 412 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 182 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 355 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 305 | 0.110 |
Why?
|
| Guideline Adherence | 4 | 2018 | 387 | 0.110 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 802 | 0.110 |
Why?
|
| Procollagen | 1 | 2014 | 14 | 0.110 |
Why?
|
| Secondary Prevention | 4 | 2018 | 217 | 0.110 |
Why?
|
| Physician Assistants | 1 | 2015 | 81 | 0.100 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 104 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 554 | 0.100 |
Why?
|
| Veterans | 3 | 2023 | 1763 | 0.100 |
Why?
|
| Phenotype | 3 | 2021 | 4497 | 0.100 |
Why?
|
| Rheumatic Fever | 1 | 2014 | 20 | 0.100 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 106 | 0.100 |
Why?
|
| Hypercholesterolemia | 2 | 2013 | 230 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 325 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2014 | 178 | 0.100 |
Why?
|
| Collagen Type I | 1 | 2014 | 110 | 0.100 |
Why?
|
| Patient Care Management | 1 | 2014 | 61 | 0.100 |
Why?
|
| Hospitals, Veterans | 2 | 2013 | 336 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 247 | 0.100 |
Why?
|
| Life Style | 2 | 2013 | 456 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2021 | 323 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2016 | 450 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 2 | 2018 | 457 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 100 | 0.100 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 26 | 0.100 |
Why?
|
| Foundations | 1 | 2013 | 24 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2016 | 624 | 0.100 |
Why?
|
| Biopsy | 3 | 2021 | 1239 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 744 | 0.100 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 59 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 294 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2019 | 561 | 0.090 |
Why?
|
| Physicians | 2 | 2019 | 635 | 0.090 |
Why?
|
| Editorial Policies | 2 | 2023 | 49 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 68 | 0.090 |
Why?
|
| Receptors, Cytokine | 3 | 2001 | 65 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2904 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 83 | 0.090 |
Why?
|
| Outpatients | 1 | 2014 | 262 | 0.090 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 19 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2012 | 242 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 789 | 0.090 |
Why?
|
| General Surgery | 1 | 2014 | 224 | 0.090 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 161 | 0.090 |
Why?
|
| Nanomedicine | 1 | 2012 | 33 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 682 | 0.090 |
Why?
|
| Program Development | 1 | 2012 | 179 | 0.090 |
Why?
|
| Congresses as Topic | 2 | 2026 | 184 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 73 | 0.090 |
Why?
|
| Vocabulary | 1 | 2011 | 20 | 0.090 |
Why?
|
| Forecasting | 1 | 2013 | 351 | 0.080 |
Why?
|
| Models, Cardiovascular | 2 | 2011 | 165 | 0.080 |
Why?
|
| Endocardium | 2 | 2021 | 45 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 239 | 0.080 |
Why?
|
| Recurrence | 2 | 2012 | 1489 | 0.080 |
Why?
|
| Central Venous Pressure | 1 | 2011 | 25 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 1071 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 708 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 2825 | 0.080 |
Why?
|
| Communication | 2 | 2026 | 543 | 0.080 |
Why?
|
| Systole | 1 | 2011 | 195 | 0.080 |
Why?
|
| Overweight | 1 | 2013 | 387 | 0.080 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 26 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 928 | 0.080 |
Why?
|
| Hospital Costs | 2 | 2022 | 188 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2010 | 59 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 126 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 383 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2012 | 232 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2026 | 732 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2009 | 1211 | 0.080 |
Why?
|
| Viral Tropism | 2 | 2020 | 55 | 0.080 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 16 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2026 | 1173 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2019 | 1223 | 0.070 |
Why?
|
| Medical Records | 1 | 2009 | 174 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2010 | 414 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 214 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2013 | 1050 | 0.070 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 15 | 0.070 |
Why?
|
| Animals | 12 | 2021 | 33912 | 0.070 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 97 | 0.070 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 134 | 0.070 |
Why?
|
| Cholesterol | 1 | 2011 | 539 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2012 | 521 | 0.070 |
Why?
|
| Metformin | 1 | 2010 | 174 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 78 | 0.070 |
Why?
|
| Etanercept | 3 | 2008 | 44 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2023 | 195 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2023 | 482 | 0.070 |
Why?
|
| Heart Rate | 3 | 2006 | 577 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 604 | 0.070 |
Why?
|
| Decision Making | 2 | 2026 | 726 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2008 | 81 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 81 | 0.060 |
Why?
|
| Seasons | 1 | 2008 | 335 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1882 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2009 | 483 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 905 | 0.060 |
Why?
|
| Adolescent | 5 | 2019 | 20987 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 389 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2026 | 27 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2026 | 55 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2026 | 21 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 2 | 2002 | 62 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 707 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 327 | 0.060 |
Why?
|
| Cardiac Output | 2 | 2020 | 153 | 0.060 |
Why?
|
| Remission Induction | 1 | 2026 | 306 | 0.060 |
Why?
|
| Common Data Elements | 2 | 2015 | 6 | 0.060 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 135 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 1618 | 0.060 |
Why?
|
| Health Services Research | 2 | 2011 | 180 | 0.060 |
Why?
|
| Heart Arrest | 2 | 2020 | 356 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 483 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 4066 | 0.050 |
Why?
|
| Heart Ventricles | 2 | 2020 | 749 | 0.050 |
Why?
|
| Equipment Design | 2 | 2020 | 512 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2020 | 807 | 0.050 |
Why?
|
| Bacteremia | 1 | 2009 | 446 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2026 | 146 | 0.050 |
Why?
|
| Counseling | 1 | 2026 | 238 | 0.050 |
Why?
|
| Potassium | 1 | 2025 | 263 | 0.050 |
Why?
|
| Information Technology | 1 | 2024 | 9 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2026 | 466 | 0.050 |
Why?
|
| Heart Atria | 1 | 2006 | 343 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 571 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2011 | 844 | 0.050 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 115 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 108 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 321 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 20 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 149 | 0.050 |
Why?
|
| Iron | 1 | 2026 | 304 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2002 | 101 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 222 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2012 | 729 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 102 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 18 | 0.050 |
Why?
|
| Biliopancreatic Diversion | 1 | 2002 | 4 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 443 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 39 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 205 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 9 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2026 | 730 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 231 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 107 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 225 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2022 | 43 | 0.040 |
Why?
|
| Risk | 1 | 2004 | 726 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 43 | 0.040 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2001 | 13 | 0.040 |
Why?
|
| Patient Participation | 1 | 2024 | 254 | 0.040 |
Why?
|
| Data Mining | 1 | 2021 | 68 | 0.040 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 132 | 0.040 |
Why?
|
| Echovirus Infections | 1 | 2020 | 2 | 0.040 |
Why?
|
| Erythema Infectiosum | 1 | 2020 | 5 | 0.040 |
Why?
|
| Coxsackievirus Infections | 1 | 2020 | 9 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 299 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 110 | 0.040 |
Why?
|
| Motor Activity | 2 | 2013 | 489 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2021 | 88 | 0.040 |
Why?
|
| Roseolovirus Infections | 1 | 2020 | 29 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 30 | 0.040 |
Why?
|
| Total Quality Management | 1 | 2000 | 22 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 345 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 16 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 32 | 0.040 |
Why?
|
| Cloud Computing | 1 | 2020 | 15 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 48 | 0.040 |
Why?
|
| HIV Infections | 2 | 2020 | 2049 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 48 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 118 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 109 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 97 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 239 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 274 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 120 | 0.040 |
Why?
|
| Smartphone | 1 | 2020 | 52 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 95 | 0.040 |
Why?
|
| Mass Screening | 2 | 2021 | 822 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 83 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 175 | 0.040 |
Why?
|
| Research | 1 | 2021 | 264 | 0.040 |
Why?
|
| Pyridines | 1 | 2001 | 255 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 205 | 0.040 |
Why?
|
| Contracts | 1 | 2019 | 11 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 394 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 197 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2003 | 385 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 292 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2003 | 477 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2015 | 401 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4697 | 0.040 |
Why?
|
| Liver | 1 | 2026 | 1796 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 365 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 223 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1998 | 33 | 0.030 |
Why?
|
| Nurses | 1 | 2019 | 65 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 676 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2020 | 294 | 0.030 |
Why?
|
| Dimerization | 1 | 1998 | 137 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 149 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 143 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2022 | 1117 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 289 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 386 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 351 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2002 | 668 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 218 | 0.030 |
Why?
|
| Algorithms | 2 | 2016 | 1680 | 0.030 |
Why?
|
| Aspirin | 1 | 2018 | 211 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2021 | 3147 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 197 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2020 | 381 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 237 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1996 | 50 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 67 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 2019 | 257 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 18 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 69 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2015 | 21 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1105 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 765 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 443 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1996 | 246 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 448 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 464 | 0.030 |
Why?
|
| Confidentiality | 1 | 2015 | 108 | 0.030 |
Why?
|
| DNA Damage | 1 | 1998 | 511 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 70 | 0.030 |
Why?
|
| Students, Medical | 1 | 2019 | 347 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Pharyngitis | 1 | 2014 | 34 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 187 | 0.030 |
Why?
|
| Mitral Valve Stenosis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2020 | 712 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 1797 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 449 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 135 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 798 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 318 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 78 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 645 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2015 | 190 | 0.020 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 15 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 224 | 0.020 |
Why?
|
| Iron Overload | 1 | 2013 | 18 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2013 | 92 | 0.020 |
Why?
|
| Patients | 1 | 2013 | 122 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2013 | 122 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 179 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 149 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 194 | 0.020 |
Why?
|
| Public Policy | 1 | 2012 | 55 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 689 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 42 | 0.020 |
Why?
|
| Rats | 1 | 1998 | 3370 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2085 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 254 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 258 | 0.020 |
Why?
|
| Family Practice | 1 | 2011 | 84 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 124 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 113 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 564 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 273 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 124 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 531 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 602 | 0.020 |
Why?
|
| Efficiency | 1 | 2009 | 74 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 117 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2009 | 88 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 165 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1224 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 563 | 0.020 |
Why?
|
| Electrooculography | 1 | 2006 | 6 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2009 | 254 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1121 | 0.020 |
Why?
|
| Electromyography | 1 | 2006 | 134 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2006 | 159 | 0.010 |
Why?
|
| Polysomnography | 1 | 2006 | 153 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2009 | 526 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2065 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2006 | 863 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 576 | 0.010 |
Why?
|
| Receptor, Endothelin B | 1 | 2001 | 6 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 2001 | 11 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2001 | 41 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2001 | 182 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2001 | 187 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 256 | 0.010 |
Why?
|
| Benchmarking | 1 | 2000 | 137 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 130 | 0.010 |
Why?
|
| Documentation | 1 | 2000 | 121 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8635 | 0.010 |
Why?
|
| Walking | 1 | 1999 | 230 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 13352 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 15110 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1319 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 670 | 0.010 |
Why?
|
| Child | 1 | 2012 | 26341 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 2323 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 4686 | 0.000 |
Why?
|